drugset
Drugs / Oxy(Gly)4-sKLH
last change Oct 2020 re-read 3 minutes ago

Oxy(Gly)4-sKLH

also known as Oxy(Gly)4-sKLH Conjugate Vaccine, Adsorbed · Oxy(Gly)4-sKLH vaccine
Developed for
opiate dependence
Investigated by
Clinilabs, Inc. · National Institute on Drug Abuse (NIDA) · New York State Psychiatric Institute

Trials 1

today NCT04458545 · Ph 1/2
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04458545 Oct 2020 → Mar 2027 expected opiate dependence New York State Psychiatric Institute Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Oxy(Gly)4-sKLH ClinicalTrials.gov intervention name — accepted as the source's own label NCT04458545 ↗
Known as Oxy(Gly)4-sKLH Conjugate Vaccine, Adsorbed “The proposed study is designed as a Phase 1a/1b clinical trial of an oxycodone vaccine (Oxy(Gly)4-sKLH Conjugate Vaccine, Adsorbed).” NCT04458545 ↗
Known as Oxy(Gly)4-sKLH vaccine “The Oxy(Gly)4-sKLH vaccine adsorbed to aluminum adjuvant (Alhydrogel®) or aluminum adjuvant as placebo, will be injected intramuscularly (IM) into the deltoid muscle.” NCT04458545 ↗
Route Intramuscular “will be injected intramuscularly (IM) into the deltoid muscle.” NCT04458545 ↗